Medications

First cell-based gene therapy approved for multiple myeloma

Abecma (idecabtagene vicleucel), a chimeric antigen receptor (CAR) T-cell therapy, was approved by the U.S. Food and Drug Administration for the treatment of multiple myeloma, the agency announced Saturday.

page 1 from 24